Tag Archives: AstraZeneca

Top Pharma News and Developments that Made Headlines in July

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

Amgen signs collaboration agreement with Array BioPharma

2000px-amgen-svg

Amgen and Array BioPharma announced a preclinical license and collaboration agreement in inflammation.

Under the agreement, the two companies will collaborate on the discovery and development of new drugs for autoimmune disorders. Amgen will be responsible for clinical development and commercialization, having exclusive rights to Array’s preclinical program. In turn, upfront and milestone payments will be made by Amgen.

 

Bavarian Nordic partnered with Johnson & Johnson for HIV, HBV shots

j-j-logo

Danish company Bavarian Nordic and Johnson & Johnson have signed a deal worth USD 879M  to develop HIV, HBV shots.

Under the terms of the deal, Bavarian Nordic is granting J&J’s Janssen unit the rights to combine MVA-BN with Janssen’s own AdVac platform in the HIV and HBV programs. In return, Janssen will pay Bavarian Nordic $10 million upfront and up to $836 million in milestones. Bavarian Nordic will design, produce and deliver the MVA needed, while Janssen will handle R&D.

 

Samsung and Merck launched Remicade biosim

merck_logo

Samsung and Merck & Co. launched Renflexis in the US. Renflexis is 35% cheaper than J&J’s anti-inflammatory med.

Last year, Pfizer launched its version, Inflectra, at a 15% discount. Renflexis is the third biosim to launch in the US after Inflectra and Sandoz’s Zarxio, a biosimilar to Amgen’s Neupogen.

 

Gilead’s Vosevi got US FDA Approval

gilead

The US Food and Drug Administration (FDA) has approved Gilead Sciences’ Vosevi tablets, a single-tablet regimen for the re-treatment of chronic hepatitis C virus (HCV) infection in adults with genotype 1, 2, 3, 4, 5 or 6 previously treated with an NS5A inhibitor-containing regimen, or with genotype 1a or 3 previously treated with a sofosbuvir-containing regimen without an NS5A inhibitor.

The approval is based on data from the Phase 3 POLARIS-1 and POLARIS-4 studies, which evaluated Vosevi during an interval of 12 weeks.

 

Novo Nordisk and Glooko launch co-marketed app

novo_nordisk-logo

As a result of Novo Nordisk’s partnership with diabetes health tech startup Glooko a new app was launched. It’s dubbed Cornerstones4Care Powered by Glooko, or the C4C app.

The app allows diabetes patients to measure and track blood glucose, activities and meals. It syncs blood glucose and activity data from a wide array of diabetes or exercise devices.

The app is free for registered C4C online users and can be downloaded from the Apple or Google app stores.

 

AstraZeneca partners with Merck to develop and commercialise cancer drugs

astrazeneca-svg

AstraZeneca and Merck & Co have entered a global oncology collaboration to co-develop and co-commercialise the AstraZeneca’s Lynparza and selumetinib for various cancer types.

Under the agreement, the companies will develop and commercialise Lynparza jointly, as monotherapy and in combination with other potential medicines. Furthermore, they will develop and commercialise Lynparza in combination with their own PD-L1 and PD-1 medicines, Imfinzi and Keytruda.

AstraZeneca and Merck will also co-develop and commercialise selumetinib, the former’s selective inhibitor of MEK, that’s being developed for several indications including thyroid cancer.

The 2 companies will share development and commercialisation costs as well as profits from product sales.

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017 and 2018, regardless of their location. The biggest congresses next year are:

  • EASL 2018 – 210 rooms in seven 4-star hotels
  • EAACI 2018 – 615 rooms in fourteen 4-star hotels
  • EHA 2018 – 1200 rooms in thirty 4-star hotels
  • ERS 2018 – 615 rooms in twenty 4-star hotels
  • EURETINA 2018 – 460 rooms in twelve 4-star hotels
  • EASD 2018 – 765 rooms in sixteen 4-star hotels
  • ECTRIMS 2018 – 620 rooms in ten hotels
  • ESMO 2018 – 1092 rooms in twenty-one 4-star hotels.

 

Advertisements

How 6 Big Pharma Companies Use Twitter to Engage with Audiences

This article is brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

Pharma companies have begun to embrace different communication channels, including social media, to promote their products, present their drug development initiatives and engage with audiences worldwide.

However, make no mistake, social media is not the same for pharma companies as it is for regular users. Without proper planning, controls and staff training, firms risk fines, sanctions and worse, damage to their reputation.

Facebook, Twitter and Pinterest are the main online networks that pharmaceutical companies are eyeing. In this article, we’ll take a look at how pharma companies like Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, Pfizer, Merck and Novartis use Twitter to maintain a close connection with their existing and potential patients.

 

Bristol-Myers Squibb

Screen Shot 2017-06-13 at 09.23.23

@bmsnews is the name of New York-based Bristol-Myers Squibb’s Twitter account. The latter was opened in April 2009 and has now has 108.000 followers. The company’s Twitter feed covers everything from drug research results and analysis, clinical collaborations with other pharma companies, to features about the company’s supply chain, and many more.

 

AstraZeneca

Screen Shot 2017-06-13 at 09.24.44

Apart from the main @AstraZeneca Twitter account, the company also has accounts for different countries (UK, US, Canada, etc) and a Twitter profile dubbed @AZhelps. The latter is destined to help people manage and support their health more confidently. The account was opened in 2009 and it currently has over 3000 followers. On the official company account, AstraZeneca posts articles and press releases related to drug discovery, tweets from different conferences, research data, etc. The account now boasts 126.000 followers.

 

GlaxoSmithKline

Screen Shot 2017-06-13 at 09.26.15

@GSK was one of the first pharma companies to be on Twitter. They created their account 10 years ago, in 2007, and now have 146.000 followers. The UK-based company also has a US version @GSKUS that it started in March 2009 and has 73.800 followers. They post R&D updates, info about conferences and events that they’re attending, studies, interviews with patients and employees, etc.

 

Pfizer

Screen Shot 2017-06-13 at 09.27.12

Apart from having separate Twitter accounts for countries like Belgium, France, Turkey, Germany, Austria, etc, @pfizer has an official Twitter profile started in 2009 which now has 206.000 followers and a channel dedicated to media announcements and investor communications dubbed @pfizer_news. Pfizer’s Twitter account is the most followed of all the big pharma Twitter accounts. It mainly focuses on the company’s initiatives in the greater therapeutic arena (like the #QuitSmoking one), cancer research, health tips, polls and surveys, etc.

 

Sanofi

Screen Shot 2017-06-13 at 09.28.33

@sanofi created its official Twitter profile in 2009 and now has 92.600 followers. The French pharma company has more than 18 Twitter accounts. It has handles for different regions – France, Canada, and the US, as well as accounts for different units like its diabetes franchise and its Genzyme unit. On the company’s official Twitter feed you can find posts related to Big Data and health initiatives, collaborations with startups to develop new health solutions, their anti counterfeiting initiatives, vaccines research and development, etc.

 

Novartis

Similar to the other pharma companies, Novartis has several Twitter handles, one for each division of the company (@NovartisPharma for the pharmaceutical division, @NovartisScience, @NovartisCancer) as well as the official page @Novartis. The latter was created in 2008 and has 216.000 followers.

Also, Novartis has one account devoted entirely to oncology clinical trials @NovartisOncCT that allows patients to find out if they qualify for trials.

On their general Twitter account, they update their audience on the latest drug research and development initiatives, post news related to partnerships and collaborations, etc.

Screen Shot 2017-06-13 at 09.29.44

In June 2014, the FDA released its social media guidance regarding the presentation of risk and benefit information which prevents pharma companies from marketing their drugs on social media without presenting the risks associated with their use. However, pharma players have found creative and useful ways of attracting and keeping their audiences engaged. Chapeau!

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017 and 2018, regardless of their location. The biggest congresses next year are:

  • EASL 2018 – 210 rooms in seven 4-star hotels
  • EAACI 2018 – 615 rooms in fourteen 4-star hotels
  • EHA 2018 – 1200 rooms in thirty 4-star hotels
  • ERS 2018 – 615 rooms in twenty 4-star hotels
  • EURETINA 2018 – 460 rooms in twelve 4-star hotels
  • EASD 2018 – 765 rooms in sixteen 4-star hotels
  • ECTRIMS 2018 – 620 rooms in ten hotels
  • ESMO 2018 – 1092 rooms in twenty-one 4-star hotels.

Top Pharma News and Developments that Made Headlines in May

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

Merck’s Keytruda got FDA approval to treat genetically ID’d tumors

merck_logo

Merck’s Keytruda was approved by the FDA to treat patients whose cancers have a specific genetic feature, making that the first time the FDA approved a cancer treatment based on a common genetic feature and not on the location where the tumor originated.

Keytruda is used for the treatment of solid tumors that have a biomarker referred to as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).

 

The FDA approved first generic Strattera for the treatment of ADHD

The first generic versions of Strattera  have been approved by the FDA to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

fda

Strattera will be marketed by Apotex Inc., Teva Pharmaceuticals USA Inc., Aurobindo Pharma Limited and Glenmark Pharmaceuticals Limited.

 

Bristol-Myers Squibb entered strategic collaboration with Array BioPharma

bms

Bristol-Myers Squibb has entered a clinical research collaboration with Array BioPharma to test the latter’s investigational MEK inhibitor, binimetinib in combination with its Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen. This could be a treatment for metastatic colorectal cancer in patients with microsatellite stable tumors.

Bristol-Myers Squibb’s Opdivo has recently been accepted for priority review in liver cancer.

 

Sanofi and Regeneron Got FDA Approval for Kevzara

Impression

Sanofi and Regeneron announced FDA approval of Kevzara (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patientswho have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX).

Kevzara is a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R), and has been shown to inhibit IL-6R mediated signaling. IL-6 is a cytokine in the body that, in excess and over time, can contribute to the inflammation associated with RA.

In the US, Kevzara will be marketed by Regeneron and Sanofi Genzyme, the specialty care global business unit of Sanofi.

 

Novartis receives FDA approval for expanded use of Zykadia

novartis

The US Food and Drug Administration approved the expanded use of Zykadia (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.

Zykadia first received accelerated approval in 2014 for patients with ALK-positive metastatic NSCLC who progressed on or are intolerant to crizotinib.

In January 2017, the FDA granted Zykadia Breakthrough Therapy designation for the first-line treatment of patients with ALK-positive metastatic NSCLC with metastases to the brain, and Priority Review for first-line ALK-positive metastatic NSCLC.

 

AstraZeneca’s Imfinzi was shown to reduce the risk of disease worsening or death in the Phase III PACIFIC trial

astrazeneca-svg

AstraZeneca and MedImmune, its global biologics research and development arm, revealed positive results for the Phase III PACIFIC trial of Imfinzi (durvalumab) as sequential treatment in patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy combined with radiation therapy.

AstraZeneca also received accelerated approval from the US FDA for Imfinzi in previously treated patients with advanced bladder cancer.

 

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017 and 2018, regardless of their location. The biggest congresses next year are:

  • EASL 2018 – 210 rooms in seven 4-star hotels
  • EAACI 2018 – 615 rooms in fourteen 4-star hotels
  • EHA 2018 – 1200 rooms in thirty 4-star hotels
  • ERS 2018 – 615 rooms in twenty 4-star hotels
  • EURETINA 2018 – 460 rooms in twelve 4-star hotels
  • EASD 2018 – 765 rooms in sixteen 4-star hotels
  • ECTRIMS 2018 – 620 rooms in ten hotels
  • ESMO 2018 – 1092 rooms in twenty-one 4-star hotels.

Top Pharma News & Developments that Made Headlines in March

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

FDA approved Roche’s OCREVUS

roche

The US Food and Drug Administration (FDA) approved Roche’s OCREVUS (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis (MS).

OCREVUS reduced relapses per year by half during the two RMS Phase III studies. Furthermore, in a separate PPMS Phase III study, OCREVUS was the first and only treatment to significantly slow disability progression and reduce signs of disease activity in the brain compared with placebo with a median follow-up of three years.

The European Medicines Agency (EMA) has validated OCREVUS’ Marketing Authorisation Application (MAA) which is currently under review.

 

AstraZeneca Partnered with Circassia

astrazeneca-svg

AstraZeneca entered a strategic collaboration with respiratory biopharmaceutical company Circassia Pharmaceuticals plc. The agreement was signed for the development and commercialisation of inhaled respiratory medicines Tudorza and Duaklir in the US.

Tudorza and Duaklir are used for the treatment of chronic obstructive pulmonary disease (COPD). While Tudorza was launched in the US in 2012, Duaklir will be submitted for US regulatory review in 2018.

Under the agreement, AstraZeneca will receive a minority equity stake in Circassia while the latter will lead the promotion of Tudorza and was granted the rights to Duaklir in the US. AstraZeneca will complete ongoing development activities and continue to manufacture and supply both medicines.

 

MedImmune Formed Alliance with Sanofi Pasteur for MEDI8897

Impression

MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, have formed an alliance to develop and commercialise potential next-generation respiratory syncytial virus antibody MEDI8897.

The two companies will jointly develop and commercialise MEDI8897, a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV).

MedImmune and Sanofi Pasteur will equally share all costs and profits.

 

Mylan in Global Settlement & License Agreements with Genentech and Roche on Herceptin

Mylan_Logo

In March, Mylan has agreed to the terms of a global settlement with Genentech and Roche in what concerns patents for Herceptin (trastuzumab). This enables Mylan to have global licenses for its trastuzumab product.

Under the agreement, Mylan will be able to commercialize its trastuzumab product in markets worldwide. The licenses pertain to all countries except Japan, Brazil and Mexico.

As part of the settlement, Mylan agreed to withdraw its pending Inter Partes Review (IPR) challenges against two US Genentech patents (patent numbers 6,407,213 and 6,331,415).

 

Boehringer Ingelheim Expanded Its Collaboration with Vanderbilt University

boehringer_ingelheim_logo-svg

Boehringer Ingelheim has entered a collaboration with Vanderbilt University. This adds to an already existing collaboration by focusing on the research and development of small molecule compounds targeting the protein SOS. This molecule activates KRAS and triggers a molecular switch that plays a key role when tackling some of the deadliest types of cancer.

This collaboration has led to discoveries that might set the scene for the development of novel cancer treatment options based on molecules that are able to block this critical cancer driver.

 

Merck’s Keytruda Got FDA Nod for Treating Blood Cancer

merck_logo

Merck got a first approval from the U.S. Food and Drug Administration (FDA) under the accelerated approval program for its immunotherapy drug Keytruda as a treatment for a type of blood cancer. Keytruda is already approved for treating lung, head and neck cancers.

FDA’s accelerated approval program allows for quicker approval of drugs that fill an unmet medical need.

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are:

February’s Top Pharma News & Developments

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

AstraZeneca entered agreement with TerSera Therapeutics for Zoladex

astrazeneca-svg

AstraZeneca entered an agreement with TerSera Therapeutics LLC for the commercial rights to Zoladex in the US and Canada. Zoladex is used to treat prostate cancer, breast cancer and several benign gynaecological disorders.

Under the agreement, TerSera is set to pay AstraZeneca USD 250 million upfront, plus USD 70 million in sales-related milestones and a quarterly share of sales in the “mid-teen percentage” range. AstraZeneca will also develop and supply Zoladex to TerSera.

 

Novo Nordisk filed for regulatory approval of semaglutide for the treatment of type 2 diabetes in Japan

novo_nordisk-logo

Novo Nordisk has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for semaglutide, a new glucagon-like peptide-1 analogue for the treatment of adults with type 2 diabetes.

This move follows the recent once-weekly semaglutide regulatory submissions to the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada and SwissMedic.

 

Allergan Launched See America

allergan_logo_tm

Allergan launched a new initiative dubbed See America, through which it aims to make vision health a priority for all US residents. Increasing awareness of the diseases that can cause blindness and enhancing access to vision care for those who need it most are the initiative’s main focus.

The launch followed the release of a report published by the National Academies of Sciences, Engineering, and Medicine (NASEM), which stressed upon the overwhelming number of Americans affected by blindness from preventable causes.

 

Amgen’s Parsabiv got FDA approval

2000px-amgen-svg

The US Food and Drug Administration (FDA) approved Amgen’s Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis.

Parsabiv is the first therapy approved for this condition in 12 years. It is also the only calcimimetic that can be administered intravenously three times a week after the hemodialysis session.

 

Roche to start second late-stage study of Alzheimer’s disease drug

roche

Roche’s partner AC Immune revealed that Roche is set to launch a second Phase III study of the experimental Alzheimer’s disease therapy crenezumab. The latter was discovered by AC Immune and out-licensed to Roche’s Genentech unit in 2006. The CREAD2 trial will enrol 750 patients with prodromal or mild Alzheimer’s disease.

 

Boehringer Ingelheim’s Giotrif got approved for lung cancer in China

boehringer_ingelheim_logo-svg

Global pharmaceutical company Boehringer Ingelheim announced that their afatinib (Giotrif), an irreversible second-generation ErbB family blocker, was approved for lung cancer in China.

Afatinib has received Imported Drugs License (IDL) status by the China Food and Drug Administration (CFDA) for locally advanced or metastatic EGFR mutation-positive lung cancer patients who have not received any prior therapy with tyrosine kinase inhibitors, as well as for patients with locally advanced or metastatic squamous cell carcinoma of the lung whose disease has progressed on or after treatment with platinum-based chemotherapy.

Afatinib is the first and only second-generation ErbB family blocker approved in China.

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are:

  • EHA 2017 – 445 rooms in fourteen 4-star hotels
  • ESMO 2017 – 440 rooms in ten 4-star hotels
  • ESC 2017 – 150 rooms in five 4-star hotels
  • EURETINA 2017 – 160 rooms in five 4-star hotels
  • EASD 2017 – 423 rooms in thirteen 4-star hotels
  • EAACI 2017 – 688 rooms in fourteen 4-star hotels

From 60 Pharma companies to 10 Big Pharma companies in 20 Years

We’ve all heard about Novartis, Pfizer, Sanofi and Roche. They’re some of the big guys in the pharma landscape, enjoying increased popularity, splitting the high budgets and revolutionizing the healthcare and pharma industry but what’s the road they took to get here? In order to answer that question, we’re going to analyze the 10 biggest pharma companies nowadays which used to be around 60 distinct companies 20 years ago. Here’s what they did to stand the test of time and grow.

best-pharmaceutical-companies

Novartis

It all dates back to 1970 when Ciba-Geigy was formed by the merger of J. R. Geigy Ltd and CIBA. In 1996, from the merger of Ciba-Geigy and Sandoz Laboratories, Novartis was born. In 2005, Novartis acquired Hexal and Eon Labs, thus growing its generic division Sandoz. A year later, in 2006, Novartis acquired full control of Chiron Corp. for USD 5.1 billion. In 2010, Novartis acquired the world’s largest eye-care company Alcon for USD 39.3 billion. Three years later, in 2012, the company bought Fougera Pharmaceuticals for USD 1.5 billion. In 2016, Novartis acquired Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD).

AstraZeneca (AZ)

AstraZeneca  was created in 1999 following the merger of Astra and Zeneca Group. In 2004, AZ completed its first big acquisition of Cambridge Antibody Technology. Later on, in 2007, it acquired MedImmune for about USD 15.2 billion. In 2012, AstraZeneca acquired Ardea Biosciences for USD 1.3 billion. One year later, it acquired Amylin from BMS for USD 4.3 billion and in 2015 acquired ZS Pharma for USD 2.7 billion. In 2015, AstraZeneca bought 55% majority stake in Acerta for USD 4 billion.

Pfizer

In 2000, Pfizer acquired American pharmaceutical company Warner–Lambert for USD 111.8 billion to bring its drug, Lipitor, to market. In 2002, Pfizer aimed to acquire full rights to Pharmacia’s product Celebrex and thus agreed to buy Pharmacia for stock valued at USD 60.0 billion. In 2009, Pfizer bought pharmaceutical company Wyeth for USD 68.0 billion. In 2015, Pfizer acquired Hospira for USD 15.2 billion and announced the merger with Allergan. The latter is considered to be one of the biggest mergers in pharma history. In 2016, Pfizer announced the successful completion of its acquisition of Medivation.

Sanofi

Sanofi resulted from the merger between Sanofi-Synthélabo and Aventis in 2004. The former was created in 1999 when Sanofi merged with Synthélabo. Aventis was formed in 1999 following the merger of Rhône-Poulenc S.A. with Hoechst Marion Roussel (HMR). The latter itself was formed in 1995 from the merger of Hoechst AG with Cassella, Roussel Uclaf and Marion Merrell Dow.

In 2011, Sanofi-Aventis acquired Genzyme and changed its name to Sanofi.

Johnson & Johnson

J&J was founded in 1886 as a medical devices, pharmaceutical and consumer packaged goods company. The pharmaceutical division is made up of Janssen & Cilag. In 2006, Janssen acquired the consumer healthcare business of Pfizer for USD 16.6 billion in what is considered to be the company’s largest M&A deals. In 2013, the company acquired Aragon Pharma and in 2014 it bought Alios BioPharma, Inc. for USD 1.75 billion.

Merck & Co.

Merck was founded in 1668 and is the world’s oldest operating chemical and pharmaceutical company. Merck & Co. was established as a subsidiary of Merck in 1891, but became an independent company in 1917. It is known as MSD (Merck Sharp and Dohme) outside of North America. In 1993, Merck purchased Medco Containment Services Inc. for USD 6 billion. In 2009, Merck merged with Schering-Plough. The latter had acquired Organon from Akzo Nobel in 2007 while Organon resulted from a merger between Diosynth and Organon in 2004. Ten years later, Merck bought Cubist Pharmaceuticals for USD 8.4 billion.

Roche

Roche’s first acquisition took place in 1994 when the company bought Syntex Corporation for USD 5.3 billion. In 2002, Roche’s Japanese subsidiary Nippon Roche merged with Chugai. Following the deal, Roche got a majority stake in the Japanese company. In 2008, Roche acquired Ventana Medical Systems for USD 3.4 billion and in 2009, the company bought Genentech for USD 46.8 billion.

Teva

Teva resulted from the merger between Assia, Zori and Teva in 1976. In 2006, Teva completed its first big acquisition of IVAX Corporation for USD 7.4 billion. In 2011, it acquired Cephalon for USD 6.8 billion. After acquiring Auspex Pharma for USD 3.5 billion in 2015, Teva completed its acquisition of Allergan’s generics business (“Actavis Generics”) in 2016.

Gilead Sciences

Gilead Sciences was founded in June 1987. Over the past 16 years, the company has made several acquisitions. The biggest ones include: CV Therapeutics for USD 1.4 billion in 2009 and USD 10.4 billion acquisition of Pharmasset in 2011.

GlaxoSmithKline (GSK)

GSK was founded in 2000 following the merger of Glaxo Wellcome and SmithKline Beecham. In 2001, GSK acquired Block Drug for USD 1.2 billion. In 2009, GSK acquired Stiefel Laboratories for USD 3.6 bn. 4 years later, in 2013, GSK acquired Human Genome Sciences (HGS) for USD 3 billion. In 2015, GSK completed the acquisition of vaccine business of Novartis and sale of its oncology business to the Swiss drug major in a global deal. Under the agreement, GSK Pharma expanded its vaccine portfolio and took over 120 employees from Novartis to boost its sales in India.

There’s so much pharma history behind all of the big names out there and the evolution is far from reaching an end. We’re looking forward to seeing what these pharma giants have in store during the next couple of years and who’s going to lead the way in the M&A sector.

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are: